BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced inducement grants for five newly-hired employees. The compensation package includes stock options to purchase 18,200 shares at $8.01 per share and restricted stock units (RSUs) covering 12,750 shares. Both options and RSUs will vest over four equal annual installments starting one year from the October 31, 2024 grant date. The stock options have a 10-year term, and all grants were made under Nasdaq Listing Rule 5635(c)(4) as employment inducements.

News Market Reaction

-4.01%

1 alert

-4.01% News Effect

On the day this news was published, BCRX declined 4.01%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.01 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

How many shares were granted in BioCryst's (BCRX) October 2024 inducement grants?

BioCryst granted options to purchase 18,200 shares and RSUs covering 12,750 shares to five newly-hired employees.

What is the exercise price for BCRX's October 2024 inducement stock options?

The stock options have an exercise price of $8.01 per share, equal to BioCryst's closing price on October 31, 2024.

What is the vesting schedule for BCRX's October 2024 inducement grants?

Both the options and RSUs vest in four equal annual installments, beginning on the one-year anniversary of the October 31, 2024 grant date.